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ANALYSIS OF DOSE, COST AND USE PATTERNS OF
ERYTHROPOIETIN STIMULATING AGENTS IN 
CANCER PATIENTS
Daniel GW1, Hurley D2,Whyte J2, Grochulski WD3,Willey VJ3,
Kallich J2
1HealthCore, Inc. and The University of Arizona,Tucson, AZ, USA,
2Amgen,Thousand Oaks, CA, USA, 3HealthCore, Inc, Wilmington, DE,
USA
OBJECTIVES: Cancer patients who develop anemia are often
treated with erythropoietin-stimulating agents (ESAs), including
darbepoetin alfa (DA) or epoetin alfa (EA). This study compared
baseline characteristics, patterns of ESA use, costs, and dosing
among cancer patients as observed in a large managed care
claims database. METHODS: Medical and pharmacy claims
from a U.S. managed care database were used to identify 15,007
unique episodes of care (7238 with DA, 7769 with EA) in cancer
patients between January 2004 and 2006. Episodes included all
ESA claims with ≤42 day gap between claims, plus a duration of
clinical beneﬁt based on the median days between consecutive
doses for each product. The dose conversion ratio was calculated
as the mean weekly dose of EA to DA. Six sensitivity analyses
examined the robustness of ﬁndings to study methods. Costs
were determined from plan allowed amounts for ESA claims.
RESULTS: The mean (±SD) number of administrations per
episode was 3.7 (±4.1) for DA and 5.3 (±6.4) for EA. The mean
ESA episode duration was 55.5 (±64.7) days for DA and 59.2
(±59.2) days for EA and median time between consecutive claims
was 15 and 8, respectively. The estimated mean weekly dose was
105 (±56) mcg for DA and 34,242 (±28,174) U for EA. The cor-
responding dose ratio is 1 : 326. In the sensitivity analyses, mean
weekly doses were sensitive to the inclusion/exclusion of dura-
tion of clinical beneﬁt (dose ratio 1 : 326 vs. 1 : 237, respectively).
Patients receiving DA differed signiﬁcantly in baseline charac-
teristics compared to patients receiving EA. When DCB adjusted
costs were compared, the mean weekly cost of Aranesp was
lower than for Procrit. CONCLUSION: ESA use differed signif-
icantly between DA and EA. Adjustments for patterns of use are
necessary to appropriately compare the drugs and their costs.
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OUTPATIENT USE OF HEMATOPOIETIC COLONY
STIMULATING FACTORS (CSF) AMONG ELDERLY CANCER
PATIENTS WITH CHEMOTHERAPY
Shih YCT, Xu Y, Elting LS
The University of Texas M.D. Anderson Cancer Center, Houston,TX,
USA
OBJECTIVES: Recent studies have established aging as a risk
factor of chemotherapy-induced neutropenia. Thus, the 2006
ASCO guideline added prophylactic use of CSF in older cancer
patients to its recommendations. Our study examined current
patterns of CSF use in outpatient settings in this population.
METHODS: We selected cancer patients with chemotherapy
from the 2001–2004 Medicare MarketScan data, a proprietary
dataset collecting Medicare and commercial claims for a group
of retirees with Medicare supplemental insurance. We deﬁned the
index date as the ﬁrst date of chemotherapy, followed patients
for 60 days, and classiﬁed high-risk patients as those whose
chemotherapy regimens had a greater than 40% risk of neu-
tropenia. We identiﬁed outpatient CSF use using HCPCS codes
and conducted logistic regression to examine factors associated
with CSF use; factors included age, gender, cancer types, risk
class, geographic regions, and the index year. A subgroup analy-
sis of the high-risk patients was also performed. RESULTS: We
found CSF use in 8.71% (5455 in 62,647) of the patients and
19.8% (754 in 3812) among high-risk patients. Compared with
patients in the age group 65–69, those in 75–79 and 80+ groups
were signiﬁcantly less likely to use CSF (OR = 0.83 CI:
0.76–0.90; OR = 0.73, CI: 0.66–0.79, respectively). High-risk
patients were more likely to use CSF (OR = 1.12, CI: 1.02–1.24),
so were those treated in more recent years. Compared with lung
cancer patients, breast cancer and lymphoma patients were 1.23
(CI: 1.15–1.41) and 1.81 (CI: 1.64–2.00) times more likely to
use CSF. Subgroup analysis showed that patients 75 and over
were signiﬁcantly less likely (OR = 0.83, CI: 0.70–0.99) to use
CSF than those under 75. CONCLUSION: The observed lower
rate in CSF use in the older age groups points to an unmet sup-
portive care need in a subgroup of patients who are more sus-
ceptible to neutropenia due to aging.
PCN36
NEW SYSTEM OF COSTLY DRUG REIMBURSEMENT IN
FRANCE:ASSESSMENT IN A TEACHING HOSPITAL
ONCOLOGY DEPARTMENT
Baylatry MT, Joly AC, Prugnaud JL,Tilleul P
Saint Antoine Hospital, Paris cedex 12, France
OBJECTIVES: The payment of costly drugs is not included in
the DRG price within the context of the French case-mix based
hospital payment system (termed T2A) since 2005/01/01. These
drugs will be reimbursed on an additional cost basis after imple-
mentation of a “best practices” agreement (good practice refer-
ence guidelines drawn up by scientiﬁc societies and registration
agencies). The objective of this study was to assess the propor-
tion of off-label costly anticancer drug use in terms of reference
guidelines in oncology and the impact of their unreimbursement
on the hospital activity. METHODS: A 18-month retrospective
study (2005/01/01–2006/06/30) was performed in oncology
department. 11 costly anticancer drugs were eligible for the addi-
tional reimbursement. 8416 adult patient prescriptions (943
patients) including at least one of the eleven studied drugs were
analysed. For each prescription, the anticancer drug cost was cal-
culated. The analysis of use was performed by drug: conformity
to the ofﬁcial labelling (indication, dose, route of administration)
and level of scientiﬁc evidence. The off-label anticancer drug use
was discussed with prescribers in drug committee. RESULTS:
The proportion of off-label costly anticancer drug use is 32%
(2693/8416 prescriptions) and represents 29% (€2,020,373/
€6,877,879) of oncology overall drug budget. Among these pre-
scriptions, 43% (1153/2693 prescriptions) were supported by 
at least one randomized phase III trial and represent 59%
(€1,191,068/€2,020,373) of the oncology costly anticancer drug
induced cost. CONCLUSION: The reference guidelines should
lead towards the good use of these drugs and allow the sick funds
to control prescriptions. However, the ofﬁcial labelling of drugs
is unable to answer to all clinical situations and cannot be the
own references for costly anticancer drug reimbursement. The
anticancer drug prescriptions from therapeutic progress (justiﬁed
off label used) need to be reimbursed to maintain quality of
cancer care in French hospitals.
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FREQUENCY AND DISTRIBUTION OF CERVICAL SCREENING
SMEARS IN HUNGARY
Boncz I1, Sebestyén A1, Betlehem J2, Oláh A2, Ember I2
1National Health Insurance Fund Administration, Budapest, Hungary,
2University of Pécs, Pécs, Hungary
OBJECTIVES: Organized nationwide screening programme for
cervical cancer was introduced in Hungary in 2003. Women
between the ages 25–65 are invited by a personal letter and a 3
years screening interval has been applied. The screening rate
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(attendance) of this programme proved to be low. Therefore we
aimed to analyze the frequency and distribution of Papanicolau
smears. METHODS: The data were derived from the ﬁnancial
database of the National Health Insurance Fund Administration
(OEP) of Hungary covering the period of 2003–2005. First we
calculated the frequency of pap smears then the distribution
according to geographical regions. Screening is deﬁned with the
cytological examination of Papanicolau smear and includes all
smears taken either within or outside of the organized pro-
gramme. RESULTS: The age speciﬁc screening rate of women
aged 25–64 years was 52,65% in 2003–2005. Distribution of
Papanicolau smears according to regions was: Central-Hungary:
28,4%, Central-Transdanubia: 10,5%, Western-Transdanubia:
9,3%, Southern-Transdanubia: 10,8%, Northern-Hungary:
13,2%, Northern-Greatplane: 14,2%, Southern-Greatplane:
13,6%. Frequency (number) of Papanicolau smears per 10.000
female population according to regions: Central-Hungary: 4685,
Central-Transdanubia: 4540, Western-Transdanubia: 4571,
Southern-Transdanubia: 5257, Northern-Hungary: 5035,
Northern-Greatplane: 4651, Southern-Greatplane: 4899. CON-
CLUSION: We found signiﬁcant inequalities in the frequency of
Papanicolua smears was the highest in the Southern-Transdanu-
bian and Northern-Hungarian regions. To increase participation
rate and to decrease within country inequalities are inportant
aims of the Hungarian nationwide organized cervical cancer
screening program.
PCN38
WITHIN COUNTRY DIFFERENCES IN MAMMOGRAPHY
COVERAGE OF THE HUNGARIAN NATIONWIDE ORGANIZED
BREAST CANCER SCREENING PROGRAMME
Boncz I1, Sebestyén A1, Döbrõssy L2, Budai A2, Kovács A2, Ember I3
1National Health Insurance Fund Administration, Budapest, Hungary,
2National Public Health and Medical Ofﬁcers Service (ÁNTSZ),
Budapest, Hungary, 3University of Pécs, Pécs, Hungary
OBJECTIVES: Nationwide organized breast cancer screening
programme was launched 2002 in Hungary for women between
the age of 45–65 with a 2 years screening interval. The aim of
the study is to analyse the within country inequalities of mam-
mography coverage of the organized programme. METHODS:
Data derive from the database of the National Health Insurance
Fund Administration (OEP) containing routinely collected ﬁnan-
cial data. The study includes all the women aged 45–64 hav-
ing either screening or diagnostic mammography before
(2000–2001) and after (2002–2003 and 2004–2005) the intro-
duction of organized screening. The regional inequalities are cal-
culated for 19 counties and Budapest as the capital (altogether
20 items). Coverage is deﬁned as the proportion of women res-
ident who have had a mammogram at least once in the previous
2 years. RESULTS: National mammography coverage was
26.7%, 54,6% and 51,6% in 2000–2001, 2002–2003 and
2004–2005 respectively. We found the highest coverage in
2000–2001 in counties having earlier pilot screening pro-
gramme: county Tolna (59.2%), county Jász-Nagykun-Szolnok
(45.1%), county Zala (39.5%). After the introduction of nation-
wide breast screening programme in 2002–2003 we found the
highest coverage in the following counties: county Szabolcs-
Szatmár-Bereg 70.8%, county Borsod-Abaúj-Zemplén 64.4%,
county Veszprém 63.9%. In 2004–2005, the following counties
received the highest coverage: county Gyõr-Moson-Sopron
(60.8%), county Szabolcs-Szatmár-Bereg 58.1% and county Vas
56.2%. The ratio of coverage between the counties with the
highest and lowest coverage was 3.5 (2000–2001), 2.6
(2002–2003) and 1.4 (2004–2005). CONCLUSION: We found
signiﬁcant within country differences in mammography cover-
age, however the gap between counties with lowest and highest
coverage became smaller after the introduction of organized
screening programme.
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GAP BETWEEN INPATIENT TREATMENT COST OF AND
MORTALITY DUE TO BREAST CANCER IN HUNGARY
Boncz I1, Sebestyén A1, Döbrõssy L2, Péntek M3, Gulácsi L4
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OBJECTIVES: The aim of this study is to analyze and compare
the distribution of inpatient care treatment cost of and mortal-
ity due to breast cancer according to age-groups. METHODS:
Data derive from the database of the National Health Insurance
Fund Administration (OEP) containing routinely collected ﬁnan-
cial data. The study includes all the women who received out-
patient and/or inpatient care treatment in 2001 ﬁnanced from
public resources of OEP. Number of deaths due to breast cancer
is from the Central Statistical Ofﬁce database. We compared the
annual out- and inpatient care treatment cost and the annual
number of deaths according to the following age groups: 0–24,
25–44, 45–64, 65–74, 75+. RESULTS: The cost distribution of
out- and inpatient care treatment cost of breast cancer was the
following (outp./inp.): 0–24 years: 0.1%/0.2%; 25–44 years:
12.4%/11.7%; 45–64 years: 59.2%/59.1%; 65–74 years:
20.9%/20.2%; 75 and over: 7.4%/8.7%. The distribution of
deaths due to breast cancer was the following: 0–24 years: 0.0%;
25–44 years: 5.0%; 45–64 years: 37.0%; 65–74 years: 22.8%;
75 and over: 35.2%. We found that in the age-group 65–74 there
is a balance between the cost distribution (20.9% and 20.2%)
and the deaths (22.8%). Women in younger age groups received
more treatment cost than its mortality would predict, while in
older age groups (75+)—responsible 35.2% of deaths—received
only 7.4% and 8.7% of out- and inpatient treatment cost respec-
tively. CONCLUSION: There is a shift between the distribution
of treatment cost of and deaths due to breast cancer in favor of
younger age-groups.
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PATTERNS OF TREATMENT OF NON SMALL CELL LUNG
CANCER (NSCLC) IN COMMUNITY PRACTICE
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OBJECTIVES: Evidence guiding NSCLC treatment has been
derived largely from controlled trials at academic centers. Much
less attention has focused on understanding NSCLC treatment
by community-based oncologists. We undertook this study to
better understand NSCLC treatment patterns and outcomes in
community-based practices. METHODS: Ten large community-
based oncology practices in the U.S. were identiﬁed. Investiga-
tors conducted chart reviews on 417 NSCLC patients treated
with chemotherapy between 2001 and 2003 who were deceased
at the time of the review. RESULTS: Of the 417 patients (54%
male, median age 68 years, mean performance status 1.2) almost
20% had a history of radiation therapy, and 9.6% had a history
of surgery. Mean survival was 10.5 months for stage IIIB patients
(n = 114) and 7.9 months for stage IV patients (n = 303). In their
ﬁrst line of chemotherapy, 55% of patients received both carbo-
platin and paclitaxel (18% in combination with radiation
therapy). Another 11% received carboplatin with either gemc-
itabine (6%) or doctaxel (5%). In contrast, monotherapy was
more common in second line therapy (docetaxel 22%, gemc-
